CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy

Journal of Neuro-Oncology

Volumn 110, Issue 1, 2012, Pages 37-48

  Waters, J Dawn ^a   Sanchez, Carlos ^b   Sahin, Ayguen ^b   Futalan, Diahnn ^a   Gonda, David D ^a   Scheer, Justin K ^a   Akers, Johnny ^a   Palanichamy, Kamalakannan ^c   Waterman, Peter ^c   Chakravarti, Arnab ^c   Weissleder, Ralph ^c   Morse, Brent ^d   Marsh, Nick ^d   Furfine, Eric ^d   Chen, Clark C ^a   Carvajal, Irvith ^d   Carter, Bob S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Adnexus   (United States)

Author keywords

AdnectinTM; CT322; Glioblastoma; Temozolomide; Vascular endothelial growth factor; Xenograft

Indexed keywords

PEGDINETANIB; PHOSPHATE BUFFERED SALINE; TEMOZOLOMIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BRAIN TUMOR; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LONG TERM CARE; MALE; MONOTHERAPY; MOUSE; MULTIMODALITY CANCER THERAPY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN SECRETION; RADIATION DOSE; TREND STUDY; TUMOR CELL; TUMOR ESCAPE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DACARBAZINE; FIBRONECTINS; GLIOMA; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; PEPTIDE FRAGMENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866343528     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0948-7     Document Type: Article

References (36)

1. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333-343. doi: 10.3171/jns.1978.49.3. 0333
2. Stupp R, Mason WP, Bent MJvd, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann JR, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
3. Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M (2010) Current therapeutic paradigms in Glioblastoma. Rev Recent Clin Trials 5:14-27
4. Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, Lamszus K (1999) Levels of vascular endothelial growth factor hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84:10-18. doi: 10.1002/(SICI)1097- 0215(19990219)84:1<10:AID-IJC3>3.0.CO;2-L
5. Plate K, Breier G, Weich H, Mennel H, Risau W (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59:520-529
6. Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848. doi: 10.1038/359845a0
7. Feldkamp MM, Lau N, Rak J, Kerbel RS, Guha A (1999) Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer 81:118-124. doi: 10.1002/(SICI)1097-0215(19990331) 81:1<118:AID-IJC20>3.0.CO;2-5
8. Zhou Y-H, Tan F, Hess KR, Yung WKA (2003) The expression of PAX6 PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9:3369-3375
9. Leon SP, Folkerth RD, Black PM (1996) Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77:362-372. doi: 10.1002/(SICI)1097-0142(19960115)77:2<362:AID-CNCR20>3.0.CO;2-Z
10. Wick W, Weller M, Weiler M, Batchelor T, Yung AWK, Platten M (2011) Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro-Oncol 13:566-579. doi: 10.1093/neuonc/nor039
11. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY (2008) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92:149-155. doi: 10.1007/s11060-008-9745-8
12. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049. doi: 10.1056/NEJMra0706596
13. Veikkola T, Alitalo K (1999) VEGFs, receptors and angiogenesis. Semin Cancer Biol 9:211-220
14. Baldwin ME, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL, Karkkainen MJ, Alitalo K, Stacker SA, Achen MG (2001) The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man. J Biol Chem 276:19166-19171. doi: 10.1074/jbc.M100097200
15. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Moller NPH, Risau W, Ullrich A (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846
16. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K (2001) Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. The EMBO. J. 20: 1223-1231. doi: 10.1093/emboj/20.6.1223
17. Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, Hara A, Kunisada T, Mori H, Iwama T (2007) VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 360:553-559. doi: 10.1016/j.bbrc.2007.06.094
18. Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16:748-754
19. Mamluk R, Carvajal IM, Morse BA, Wong H, Abramowitz J, Aslanian S, Lim AC, Gokemeijer J, Storek MJ, Lee J, Gosselin M, Wright MC, Camphausen RT, Wang J, Chen Y, Miller K, Sanders K, Short S, Sperinde J, Prasad G, Williams S, Kerbel R, Ebos J, Mutsaers A, Mendlein JD, Harris AS, Furfine ES (2010) Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. Monoclon Antib 2: 199-208
20. Lipovsek D (2010) Adnectins: engineered target-binding protein therapeutics. Prot Eng Des Sel 24:3-9. doi: 10.1093/protein/gzq097
21. Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17:363-371. doi: 10.1158/1078-0432.ccr-10-1411
22. Murphy GJ, Mostoslavsky G, Kotton DN, Mulligan RC (2006) Exogenous control of mammalian gene expression via modulation of translational termination. Nat Med 12:1093-1099. doi: 10.1038/nm1376
23. Shapiro WR (1974) The chemotherapy of intracerebral vs subcutaneous murine gliomas: a comparative study of the effect of VM 26. Arch Neurol 30:222-226
24. Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312:1171-1175. doi: 10.1126/science.1125950
25. Hudis CA (2005) Clinical implications of antiangiogenic therapies. Oncology 19:26-31
26. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62. doi: 10.1126/science.1104819
27. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542-2552. doi: 10.1200/jco.2008.19.9356
28. Gerstner ER, Duda DG, Tomaso Ed, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT (2009) VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 6:229-236. doi: 10.1038/nrclinonc.2009.14
29. Gerstner ER, Frosch MP, Batchelor TT (2010) Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 28:e91-e93
30. Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin(R)) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131-1138. doi: 10.1634/theoncologist.2009-0121
31. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II Study of Cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in Patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823. doi: 10.1200/jco.2009.26.3988
32. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, DeAngelis LM, Yung WKA, Chen A, Prados MD, Wen PY (2011) Phase II Study of aflibercept in recurrent malignant glioma: a North American brain tumor consortium study. J Clin Oncol 29:2689-2695. doi: 10.1200/jco.2010.34.1636
33. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T (2010) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142-148. doi: 10.1200/jco.2010.30.2729
34. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Paul MJ Clement, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28
35. Beal K, Abrey LE, Gutin PH (2011) Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 6:2. doi: 10.1186/1748-717X-6-2
36. Schiff DRD, Kesari S, Mikkelsen T, De Groot JF, Fichtel L, Coyle TE, Wong EEC, Silver B (2010) Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM) [abstract]. J Clin Oncol 28:182s